Real-time prices are available during market hours (9:30 AM to 4:00 PM EST). If the symbol has pre-market or post-market trades, that information will also be reflected along with the last (closing) price from the symbol's exchange. Volume always reflects consolidated markets. During market hours, the real-time Cboe BZX price displays and new trade updates are updated on the page (as indicated by a "flash"). Real-time prices are provided by Cboe BZX Exchange on individual U.S.
TYME STOCK NEWS TRIAL
The company plans to begin enrollment for a Phase 2 trial of the therapy for breast cancer in the third quarter of 2021 and continue enrollment for its Phase 2 trial in high-risk metastatic sarcomas. The treatment is currently being evaluated in an “adaptive randomized Phase 2/3 clinical trial for patients with second-line pancreatic cancer.” Tyme says clinical trials have shown that therapy to be effective against 15 different cancers including pancreatic, lung, breast, prostate, and sarcoma cancers. Its lead therapy is a novel compound known as SM-88. The company says its “therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.” Tyme’s work is “developing cancer metabolism-based therapies (CMBTs™) that are intended to be broadly effective across tumor types and have low toxicity profiles.” and Tyme plans to conduct further studies and trials this year. It has not yet been approved to be used in the U.S. The company said the technology is “an investigational method of drug delivery in the pre-clinical phase of development”. Tyme’s Chief Scientific Officer Steve Hoffman said, “This technology could provide Tyme an opportunity to expand its current cancer-metabolism based approach with a drug delivery platform that’s aimed to deliver toxic therapies in a targeted manner that could offer improved safety and efficacy for a range of anticancer drugs.” “This method of delivery is predicated on the metabolic phenomenon in which cancer cells consume higher quantities of non-essential amino acids, including tyrosine, from their surrounding environment to support their growth because they cannot make enough of these amino acids.” The company says it “has developed a technology by which the tyrosine isomer racemetyrosine (α-methylparatyrosine) can be fused with a second therapeutic agent in a manner that creates a fusion compound that may allow targeted delivery to the cancer cells in a novel manner.” That patent covers Tyme’s technology to provide “targeted delivery of therapeutics to cancer cells.” The rally comes after Tyme Technologies said, “it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform.”
TYME stock jumped as much as 70% in today’s session and at writing, shares were holding about 60% higher. Tyme Technologies Inc (NASDAQ: TYME) is running today after the biotech announced additional patents for its drug-delivery technology. Even though this approach is still in its early stages, if proven, it has the potential to be a broadly leveraged platform technology.” -Richie Cunningham, CEO of Tyme “This delivery technology is another example of our innovative spirit at Tyme.
0 kommentar(er)
